SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 235 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $353,338 | +41.3% | 12,818 | +54.0% | 0.00% | – |
| Q2 2023 | $250,101 | -16.3% | 8,322 | +0.9% | 0.00% | -100.0% |
| Q1 2023 | $298,878 | +0.3% | 8,251 | -1.1% | 0.00% | 0.0% |
| Q4 2022 | $297,937 | -63.0% | 8,345 | -65.0% | 0.00% | -50.0% |
| Q3 2022 | $806,000 | +534.6% | 23,840 | +438.5% | 0.00% | – |
| Q2 2022 | $127,000 | -8.0% | 4,427 | +4.0% | 0.00% | – |
| Q1 2022 | $138,000 | +7.8% | 4,258 | -3.0% | 0.00% | – |
| Q4 2021 | $128,000 | +19.6% | 4,389 | +9.2% | 0.00% | – |
| Q3 2021 | $107,000 | -17.1% | 4,019 | -3.5% | 0.00% | – |
| Q2 2021 | $129,000 | +24.0% | 4,164 | +4.2% | 0.00% | – |
| Q1 2021 | $104,000 | +173.7% | 3,995 | +169.8% | 0.00% | – |
| Q4 2020 | $38,000 | -56.3% | 1,481 | -64.4% | 0.00% | – |
| Q3 2020 | $87,000 | -8.4% | 4,161 | +3.1% | 0.00% | – |
| Q2 2020 | $95,000 | +50.8% | 4,037 | +15.1% | 0.00% | – |
| Q1 2020 | $63,000 | – | 3,508 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HealthInvest Partners AB | 335,000 | $8,934,000 | 13.38% |
| ASHFORD CAPITAL MANAGEMENT INC | 1,016,665 | $27,114,000 | 2.46% |
| Bruce & Co., Inc. | 402,105 | $10,724,000 | 2.28% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 297,500 | $7,934,000 | 1.91% |
| ARMISTICE CAPITAL, LLC | 3,900,000 | $104,013,000 | 1.76% |
| Bridge City Capital, LLC | 108,884 | $2,904,000 | 1.32% |
| S&T BANK/PA | 316,098 | $8,430,000 | 1.31% |
| Kent Lake Capital LLC | 100,000 | $2,667,000 | 1.15% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 331,140 | $8,832,000 | 1.02% |
| Prairiewood Capital, LLC | 45,297 | $1,208,000 | 0.99% |